Risks of clinical trial protocol amendments according to duration of the trial

A. Eleskina, N. V. Pyatigorskaya, O. Filippova
{"title":"Risks of clinical trial protocol amendments according to duration of the trial","authors":"A. Eleskina, N. V. Pyatigorskaya, O. Filippova","doi":"10.37489/2588-0519-2023-2-35-41","DOIUrl":null,"url":null,"abstract":"Background. No clinical trial could be initiated and conducted without appropriate clinical trial protocol. Any change in information relating to patients’ safety and health during the trial must be recorded and approved by a form of amendment to the clinical trial protocol, which is a time-consuming and financially expensive process for the Sponsors of these studies.Goal. To analyze the probability of releasing of clinical trials protocols amendments and to determine the most \"pregnable\" period for their occurrence in the course of the trials.Materials and Methods. The results of clinical trial protocols analysis are presented, which were approved by Russian Health Authorities between three years from 2017 to 2019 inclusive. In total, 20 protocols and 39 amendments were analyzed. Results. In the first year of the study, 21 amendments were issued, representing slightly more than half (54%) of the total number of amendments. During the second year, 12 amendments were issued, (31%). For the third year of the trial, only 3 amendments (7%) were made and for the fourth — 4, which is 8% of the total.Conclusion. The largest number of protocol amendments came out at first two years of clinical trial. Thus, they are the most \"dangerous\" years in the life of a clinical study in connection with the examination of developed protocol in real life. These first two years show how carefully the protocol was designed, how it meets the requirements of regulatory authorities, criteria and recommendations of professional associations, how feasible and effective the various criteria and procedures are.","PeriodicalId":326764,"journal":{"name":"Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37489/2588-0519-2023-2-35-41","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background. No clinical trial could be initiated and conducted without appropriate clinical trial protocol. Any change in information relating to patients’ safety and health during the trial must be recorded and approved by a form of amendment to the clinical trial protocol, which is a time-consuming and financially expensive process for the Sponsors of these studies.Goal. To analyze the probability of releasing of clinical trials protocols amendments and to determine the most "pregnable" period for their occurrence in the course of the trials.Materials and Methods. The results of clinical trial protocols analysis are presented, which were approved by Russian Health Authorities between three years from 2017 to 2019 inclusive. In total, 20 protocols and 39 amendments were analyzed. Results. In the first year of the study, 21 amendments were issued, representing slightly more than half (54%) of the total number of amendments. During the second year, 12 amendments were issued, (31%). For the third year of the trial, only 3 amendments (7%) were made and for the fourth — 4, which is 8% of the total.Conclusion. The largest number of protocol amendments came out at first two years of clinical trial. Thus, they are the most "dangerous" years in the life of a clinical study in connection with the examination of developed protocol in real life. These first two years show how carefully the protocol was designed, how it meets the requirements of regulatory authorities, criteria and recommendations of professional associations, how feasible and effective the various criteria and procedures are.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
根据试验持续时间修改临床试验方案的风险
背景。没有适当的临床试验方案,任何临床试验都不能启动和进行。在试验期间,与患者安全和健康有关的信息的任何变化都必须记录下来,并通过对临床试验方案的某种形式的修订获得批准,这对这些研究的发起人来说是一个耗时且经济昂贵的过程。分析临床试验方案修订发布的可能性,并确定其在试验过程中发生的最“可孕”期。材料与方法。本文介绍了俄罗斯卫生当局在2017年至2019年(含2019年)三年间批准的临床试验方案分析结果。总共分析了20个方案和39个修正案。结果。在研究的第一年,发布了21项修正案,占修正案总数的一半多一点(54%)。在第二年,颁布了12项修正案(31%)。在试验的第三年,仅进行了3次修改(7%),第四年进行了4次修改,占总数的8%。在临床试验的头两年出现了最多的方案修改。因此,它们是临床研究生命中最“危险”的年份,与现实生活中开发方案的检查有关。头两年的情况表明,该方案的设计是多么仔细,它是如何满足监管机构的要求、标准和专业协会的建议的,各种标准和程序是多么可行和有效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Possibility analysis of antiepileptic drugs import substitution in the Russian Federation Ineffectiveness of carbapenems in real-world clinical practice according to therapeutic drug monitoring data and Roszdravnadzor AIS reports Pharmacotherapy with alpha-1 adrenergic blockers and lipid spectrum correction in patients with urinary disorders Medical and biological research data Focus on lomefloxacin: effectiveness and safety
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1